ImageFile1 = 2C-I.svg
ImageSize1 = 180px
ImageFileL2 = 2C-I-3d-sticks.png
ImageSizeL2 = 100px
ImageFileR2 = 2C-I animation.gif
ImageSizeR2 = 120px
IUPACName = 2,5-Dimethoxy-4-iodophenethylamine
Section1 = Chembox Identifiers
CASNo = 69587-11-7
SMILES = NCCC1=C(OC)C=C(I)C(OC)=C1
Section2 = Chembox Properties
C=10 | H=14 | I=1 | N=1 | O=2
MolarMass = 307.13 g/mol
MeltingPt = 246 °C
Section3 = Chembox Hazards
2C-I is a psychedelic drug and
phenethylamineof the 2C family. It was developed and popularized by Alexander Shulgin. It was described in Shulgin’s book "PiHKAL (Phenethylamines i Have Known And Loved)". The drug is used recreationally and as an entheogenbut no medical or industrial uses have been reported yet. It is mostly commonly encountered in the form of its hydrochloride salt, a fluffy, sparkling white powder, and has also been pressed into tabletform.
In the early
2000s, 2C-I was sold in Dutch smart shops, after 2C-B - which was previously sold - was banned. In April 2003, 2C-I was also banned in the Netherlands, along with 3 other 2C-x phenethylamines previously sold in Dutch smartshops for short periods of time. During the same period, 2C-I also became available in powder form from several onlinevendors of research chemicals in the United States, Asia, and Western-Europe. In 2002and 2003, tablets of 2C-I were being sold in nightclubsand at raves in Denmarkand in the United Kingdomas a club drug. 2C-I is often referred to as SlippyBitz.Fact|date=October 2007.
2C-I is generally taken orally, although it can also be insufflated, or administered rectally as well (though 2C-I often causes considerable pain upon
insufflation). There have also been a few reports of intramuscular and intravenous injections. An oral recreational dose of 2C-I is commonly between 10mg and 25mg, although doses as low as 2mg have been reported to be active. The onset of effects usually occurs within an hour, and the effects of the drug typically last somewhere in the range of 5 to 12 hours. The effects of the drug are often described as quite similar to those of its chemical relative 2C-B, combining psychedelicor hallucinogenic effects typical of drugs such as LSDwith the empathogenic or entactogenic effects of drugs such as MDMA(ecstasy). Some users report that the effects are more mental and less sensory than those of 2C-B. The feelings have been known to resemble that of childhood blissFact|date=January 2008. Users of 2C-I do, however, tend to report a physical stimulanteffect, often quite strong and cleanFact|date=January 2008. Although unpleasant physical side effects such as muscle tension, nausea, and vomiting have been reported, their incidence in the use of 2C-I appears to be less common than in the use of some of the other closely related phenethylamines such as 2C-T-2and 2C-T-7.
researchhas been conducted on the toxicityof 2C-I. No deaths have been attributed to the drug and several large doses (100+ milligrams) have been survived. There have been no reports of physical dependence or addiction. Comparisons with similar compounds suggest that use of 2C-I is unlikely to result in physical dependence.
2C-I is an illegal, controlled substance in several European nations, including
Denmark, Germany, Greece, Ireland, the Netherlands, Poland, Spainand the United Kingdom.In December 2003, the European Councilissued a binding order compelling all EU member states to ban 2C-I within three months. 2C-I is unscheduled and unregulated in the United States, however its close similarity in structure and effects to 2C-Bcould potentially subject possession and sale of 2C-I to prosecution under the Federal Analog Act, if it is intended for human consumption. This seems to be the tactic the federal government is taking in the wake of the DEA's Operation Web Tryp.
Recreational drug use
* [http://www.erowid.org/chemicals/2ci/2ci.shtml Erowid 2C-I Vault]
* [http://www.erowid.org/library/books_online/pihkal/pihkal033.shtml 2C-I Entry in PiHKAL]
* [http://www.thesite.org/drinkanddrugs/drugsafety/drugsatoz/2cb2ci 2CB, 2C-i - TheSite.org]
Wikimedia Foundation. 2010.